EMA Backs Insmed’s Brinsupri And Sanofi’s Wayrilz, Rejects Rezurock

 
• By Eliza Slawther
  
plaque psoriasis
Insmed’s Brinsupri and Sanofri’s Wayrilz are on track for pan-EU approval (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from EU CHMP

More from Product Reviews